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Introduction
Metabolic syndrome (MetS) is described as a cluster of 
several commonly occurring disorders including ab-
dominal obesity, hypertension (HT) (≥ 130/85 mmHg), 
carbohydrates disorders such as impaired fasting 
glucose or type 2 diabetes mellitus (DM2T), and lipids 
disorders such as hypertriglyceridaemia (≠TG) and low 
level of high-density-lipoprotein cholesterol (ØHDL-C) 
[1]. Insulin resistance (IR) is defined as a glucose ho-
moeostasis disorder involving a decreased sensitivity of 
muscles, adipose tissue, liver, and other body tissues to 
insulin, despite its normal or increased concentration in 
blood [2]. The gold-standard method in the diagnosis of 
IR is the metabolic clamp, but it is mainly used in clinical 
trials, so we often assess the IR using various indicators, 
for example HOmeostasis Model Assessment — Insu-
lin Resistance (HOMA-IR). IR is common in people 
with central obesity and is an additional risk factor for 
atherosclerotic and nonatherosclerotic cardiovascular 
disease (CVD). 
The aim of our study was to assess the level of IR in 
patients with metabolic syndrome, depending on its 
components, measured with the HOMA-IR index and 
hyperinsulinaemic-euglycaemic clamp.
Material and methods
The study group included 424 subjects with MetS (260 females, 
164 males). All patients were recruited for 24 months (for September 
2016 to August 2018) from the Internal Ward of the District Hospi-
tal in Wąbrzeźno, Poland and the Department of Endocrinology 
and Diabetology Collegium Medicum in Bydgoszcz, Poland. The 
diagnosis of the MetS was made on the basis of the International 
Diabetes Federation (IDF) criteria (Tab. 1). MetS diagnosis was 
established when three or more criteria were met. 
All procedures were performed after 12 h of fasting. Anthro-
pometric measurements including height, weight, and waist 
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distribution (Shapiro-Wilk test) was performed, followed by the 
ANOVA test. The results were considered statistically significant 
when p < 0.05. 
The study was approved by the Bioethics Committee of the clinical 
hospital in Bydgoszcz (KB 219/2016), before its commencement. 
Results
The characteristics of the study group are described 
in Table 2. We noted some differences between the 
female and male groups. The difference between sexes 
(260 vs. 164; p < 0.05), the level of TG (133.6 vs. 159.7; 
p < 0.05), and the occurrence of ≠TG [84/260 (32.3%) 
vs. 78/164 (48.2%); p < 0.05) were statistically significant. 
It did not have an influence on the IR results.
All patients of the study group were diagnosed 
with obesity, 73.5% with high fasting glucose levels, 
66.9% with HT, 48.3% with lower level of HDL-C, and 
38.2% with increased concentration of TG. Then the 
study group was divided into 6 subgroups accord-
ing to the constellation of 3 particular components of 
MetS (Tab. 3). IR of different degree was diagnosed in 
all patients, both males and females. Figures 1 and 2 
show the level of IR in particular subgroups depend-
ing on the type of measure. The highest level of IR was 
observed in patients with central obesity accompanied 
by DM2T and ≠TG.
Discussion
Insulin resistance may be asymptomatic or present 
a variety of disorders, such as impairment of glucose 
tolerance, DM2T, as well as hypercholesterolaemia, 
hypertriglyceridaemia, obesity, and arterial hyperten-
sion. Bonora et al. [3] in their study showed that the 
prevalence of IR was 58% in hypertension subjects, 
84.2% in ≠TG subjects, 88.1% in subjects with ØHDL-C, 
and 83.9% in DM2T subjects. 
The results of available studies indicate a relation-
ship between IR and the risk of developing CVD. Gast 
et al. [4] in their meta-analysis of 65 studies showed 
a strong correlation between IR, evaluated by HOMA 
index, and risk of CVD. IR can promote the develop-
ment of atherosclerosis through elevated glucose and 
insulin concentrations, but also through mechanisms 
circumference (WC) were obtained from all participants. BMI was 
calculated as body weight (in kilograms) divided by the square of 
body height (in metres). WC was measured by placing a measur-
ing tape around the waist at the upper point of the iliac crest. 
Systolic and diastolic blood pressure were measured in the sitting 
position after 15 min of rest using an appropriately sized cuff on 
both upper extremities. Patients were seated quietly with their 
feet on the floor, and the blood pressure readings were taken at 
1-min intervals. An average of both measurements was calculated 
and used for data analysis. Arterial hypertension was diagnosed 
according to the IDF definition. Levels of fasting total plasma 
cholesterol (TC), triglycerides (TG), high-density-lipoprotein 
cholesterol (HDL-C), and fasting blood glucose (FBG) were evalu-
ated in all patients. Low-density-lipoprotein cholesterol (LDL-C) 
was calculated using the Friedewald formula. Non-high-density-
lipoprotein cholesterol (non-HDL-C) was figured on the base of 
the following formula: 
TC – HDL-C.
In patients with abnormal fasting glycaemia values and waist cir-
cumference > 80 cm in women or > 94 cm in men, an oral glucose 
tolerance test (OGTT) was performed to determine glycaemia in the 
fasting state and 2 hours after the administration of 75 g of glucose, 
to diagnose DM2T or pre-diabetes. All tests were performed at the 
Department of Laboratory Medicine, Nicolaus Copernicus Univer-
sity, Collegium Medicum, Bydgoszcz, Poland using a Horiba ABX 
Pentra 400 analyser (Horiba ABX, Montpelier, France).
Exclusion criteria were as follows: a history of heart surgery or other 
cardiovascular interventions, congenital defects of the heart, cardiac 
rhythm disorders, pregnancy, electrolyte disorders, inflammation, 
anaemia, prostate disease, and Cushing’s syndrome. A self-reported 
history of medical and psychiatric problems, including a list of all 
currently prescribed medications, was obtained from each partici-
pant. Also subjects after stroke or with dementia were excluded, 
as were those presenting other conditions that compromised 
cognition, such as depression, anxiety, taking psychotropic drugs, 
psychiatric diseases, and history of alcohol or chemical addiction 
or uncorrected visual or hearing disorder. 
To evaluate and measure IR, a hyperinsulinaemic-euglycaemic 
clamp was performed in each patient. The method involves quan-
tification of 20% glucose solution administered to the patient to 
maintain a constant glycaemia (90–100 md/dL) during a 120-min-
ute insulin infusion. Plasma glucose was analysed with a Yellow 
Springs Instruments 2300STAT Glucose Analyzer. Plasma insulin 
was measured by chemiluminescent immuno-assays on an Im-
mulite 2000 Analyzer.
Insulin resistance was also determined through HOMA-IR. It was 
calculated using the following equation:
(Fasting glucose level [mg/dL]) × (Fasting insulin level [µU/mL]/405).
The physiological value of the index is 1.0. Higher values are 
indicative of IR. 
Statistical analysis was performed using the Statistica 8.0 soft-
ware (StatSoft Poland, Bydgoszcz). The results were expressed 
as mean ± standard deviation (SD). The normality test of the 
Table 1. International Diabetes Federation (IDF) criteria of metabolic syndrome
Abdominal obesity [cm] F ≥ 80 or M ≥ 94
Arterial hypertension [mm Hg] ≥ 130/85 or treated for arterial hypertension
Triglycerides [mg/dL] ≥ 150 [1.7 mmol/L] or treated for dyslipidaemia
HDL-C [mg/dL] < 50 [1.3 mmol/L] in women and < 40 [1.0 mmol/L] in men
Fasting glycaemia [mg/dL] ≥ 100 [5.6 mmol/L] or treated for diabetes
HDL-C — high-density lipoprotein cholesterol
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that involve dyslipidaemia, hypertension, and inflam-
mation. 
In patients with MetS, where multiple metabolic 
disorders are present, the IR can be found in the vast 
majority of subjects [3]. Its severity depends on 
a constellation of individual components of MetS that 
occur in a given patient. In our study, IR of different 
degree was diagnosed in all patients. All patients were 
diagnosed with obesity. In the study subgroup with 
obesity, DM2T, and ≠TG the highest IR, measured by 
hyperinsulinaemic-euglycaemic clamp, was found. 
Also, Juarez-Lopez et al. [5] revealed that the highest 
IR is found in patients with increased WC, DMt2, and 
≠TG. Abbasi et al. [6] showed in their study including 
587 apparently healthy individuals with normal FBG 
or prediabetes that hypertriglyceridaemia (fasting 
Table 2. The characteristics of the study group
Parameters Total Female Male p < 0.05
N (%) 424 260 (61.32%) 164 (38.67%) p < 0.05
Age [y] ± SD 61.3 ± 4.8 60.8 ± 5.1 62.1 ± 4.3 NS
BMI [kg/m2] ± SD 31.64 ± 1,3 31.48 ± 1.2 31.91 ± 1.5 NS
WC [cm] ± SD 109.1 ± 3.7 107.1 ± 3.4 112.5 ± 4.3 NS
SBP [mm Hg] ± SD 144.6 ± 11.2 144.1 ± 10.6 145.8 ± 11.5 NS
DBP [mm Hg] ± SD 92.1 ± 6.3 91.3 ± 6.2 93.5 ± 6.5 NS
LDL-C [mg/dL] ± SD 103.1 ± 22.7 102.1 ± 22.1 104.8 ± 23.0 NS
HDL-C [mg/dL] ± SD 43.9 ± 6.4 47.2 ± 6.9 38.8 ± 5.3 NS
TG [mg/dL] ± SD 143.7 ± 32.1 133.6 ± 26.5 159.7 ± 40.1 p < 0.05
Non-HDL-C [mg/dL] ± SD 129.3 ± 26.4 125.9 ± 24.2 134.8 ± 29.1 NS
IFG (n;%) 140/424(33%) 76/260(29.2%) 64/164(39%) NS
DM2T (n;%) 172/424(40.5%) 110/260(42.3%) 62/164(37.8%) NS
HT (n;%) 284/424 (66.9%) 172/260 (66.1%) 112/164 (68.3%) NS
ØHDL-C (n;%) 205/424 (48.3%) 126/260 (48.4%) 79/164 (48.2%) NS
≠TG (n;%) 162/424(38.2%) 84/260 (32.3%) 78/164 (48.2%) p < 0.05
BMI — body mass index; WC — waist circumference; SBP — systolic blood pressure; DBP — diastolic blood pressure; LDL-C — low-density lipoprotein cholesterol; 
HDL-C — high-density lipoprotein cholesterol; TG — triglycerides; IFG — impaired fasting glycaemia; DM2T — diabetes mellitus type 2; HT — hypertension;  
SD — standard deviation; NS — non significant
Table 3. The characteristics of the metabolic syndrome (MetS) subgroups according to the constellation of 3 particular 
components of MetS
Parameters O + HT + ≠TG
O + HT  
+ ØHDL-C O + HT + IFG O + HT + DM2T
O + DM2T  
+ ≠TG
O + DM2T  
+ ØHDL-C
n 94 71 66 110 68 114
Sex
F M F M F M F M F M F M
48 46 42 29 34 32 74 36 36 32 64 50
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[mg/min/kg bw] 3.44 3.40 4.14 4.09 3.79 3.76 2.69 2.59 2.47 2.42 2.99 2.94
HOMA-IR 3.40 3.42 2.79 2.84 3.96 4.01 5.23 5.38 5.73 5.82 4.27 4.35
O — obesity; HT — hypertension; ≠TG — hypertriglyceridaemia; IFG — impaired fasting glucose; DM2T — type 2 diabetes mellitus; ØHDL-C — low level 
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TG concentration ≥ 1.7 mmol/L) identified a subset 
of individuals with prediabetes, who had a higher 
mean steady-state plasma glucose concentration dur-
ing the insulin suppression test (11.3 ± 3.5 mmol/L 
vs. 9.3 ± 3.9 mmol/L, p < 0.001) and were more likely 
to be IR (66% vs. 39%, p < 0.001), and had a more ad-
verse coronary heart disease (CHD) risk factor profile. 
Many other authors in their studies show a relationship 
between IR and MetS components, such as hyperlipi-
daemia [5, 7]. IR may be an underlying mechanism lead-
ing to dyslipidaemia featuring increased TG, reduced 
high-density lipoprotein, and the presence of small, 
dense LDL [7]. The key pathological mechanism un-
derlying the dyslipidaemia commonly observed in IR 
states is dysregulation of VLDL production, particularly 
increased hepatic secretion of large amounts of very 
low-density lipoprotein (VLDL1). There are a large 
number of them in the blood, and changes in lipase ac-
tivity and lipid transfer proteins, accompanying obesity 
and IR, modulate plasma lipoprotein metabolism, lead-
Figure 2. Insulin resistance in separate subgroups depending on the constellation of particular components of MetS measured by 
hyperinsulinaemic-euglycaemic clamp. O — obesity; HT — hypertension; ≠TG — hypertriglyceridaemia; IFG — impaired fasting 

























































Figure 1. Insulin resistance in separate subgroups depending on constellation of particular components of metabolic syndrome (MetS) 
measured by HOMA-IR. O — obesity; HT — hypertension; ≠TG — hypertriglyceridemia; IFG — impaired fasting glucose; DM2T 
— type 2 diabetes mellitus; ØHDL-C — low level of high-density-lipoprotein cholesterol
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ing to the formation of lipoproteins with an increased 
atherogenic potential. Under physiological conditions, 
insulin reduces the production of VLDL1 as a result of 
inhibition of the mobilization of free fatty acids (FFA) 
from peripheral tissues, as well as by stimulating apo 
B degradation and inhibition of the synthesis of the 
microsomal triglyceride transport protein in the liver. 
In the state of IR, the supply of TG in the liver increases, 
and at the same time the inhibitory effect of insulin on 
the synthesis of VLDL1 disappears. As a result, the liver 
produces more particles of this type. TGs incorporated 
into VLDL particles arise primarily as a result of the 
esterification of FFAs, which are absorbed by the liver 
from blood in proportion to their concentration. The 
main source of FFA is adipose tissue. In the state of 
IR, the inflow of FFAs from adipose tissue to the liver 
increases. This is due to a decrease in lipogenesis in 
adipose tissue. Its efficiency depends to a large extent 
on glucose uptake, the a-glycerophosphate precursor 
necessary for the synthesis of TG in adipose tissue. 
Thus, reduction of insulin sensitivity reduces not only 
glucose uptake, but also uptake of FFA by adipose tis-
sue. In addition, insulin is a factor that inhibits intracel-
lular hormone-sensitive lipase, which plays a major role 
in the process of TG hydrolysis in adipose tissue. In IR, 
therefore, there is also an increased release of FFA from 
adipose tissue. The inflow of FFA to the liver inhibits 
insulin-stimulated apo B degradation and stimulates 
the increase of VLDL synthesis [8].
The second subgroup with the highest IR comprised 
those with obesity, diabetes, and hypertension. IR is 
common in patients with HT. The results of the available 
studies show that the prevalence of IR in HT patients 
was 58% [3]. It has been shown that high blood pressure 
and high insulin levels are associated, independently 
of weight or BMI. However, the association between 
IR and HT is not as strong as between IR and dyslipi-
daemia. Approximately 50% of hypertensive patients 
are IR [7]. In the pathogenesis of HT associated with 
abdominal obesity, IR and hyperinsulinaemia, as a com-
pensatory response to IR, are particularly important [9, 
10]. Hyperinsulinaemia activating numerous tubular 
sodium transport systems in the kidneys increases so-
dium and water retention by about 30–40%. This can 
be associated with a volume-dependent HT [11–13]. 
However, it is not known how often volume-dependent 
HT is present in IR individuals and patients with DM2T. 
Hyperinsulinaemia also stimulates the sympathetic 
nervous system [12, 14]. There is evidence suggesting 
that overaction of the sympathetic system is present 
in obese and IR individuals. However, it has not been 
proven that this is a primary defect in these patients 
[9]. Another possible link between HT and IR can be 
abnormalities in vasodilatation and blood flow. Insulin 
affects the transmembrane transport of ions and causes 
vasodilatation when administered intravenously in nor-
mal subjects. This reaction is deficient in patients with 
obesity and IR and in DM2T patients. IR and hyper-
insulinaemia can lead to ionic disturbances inside the 
vascular wall cells, leading to their remodelling (muscle 
hypertrophy) and increased contractility, narrowing of 
the lumen of resistance vessels, and the development 
of HT. Insulin also induces oxidative stress, leading 
to free-radical damage that impairs the function of 
endothelial cells and induces a mitogenic effect on the 
myocardium [15]. 
There were some limitations to our study. Antidia-
betic drugs and insulin were used in some patients, 
which may have had some impact on the assessment 
of IR.
Conclusions
The occurrence of IR in patients with MetS is obvi-
ous. However, despite the fact that they are high or 
very high cardiovascular risk patients, they are not 
a homogeneous group. Such patients differ from each 
other depending on the presence and constellation of 
particular disorders that make up the diagnosis of the 
MetS. Patients with MetS are a heterogeneous group dif-
fering in degree of IR and the risk of CVD. The results of 
our study show that the highest IR is observed in patients 
with central obesity accompanied by DM2T and ≠TG. 
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